ATI RN
ATI Pharmacology Proctored
1. What is the antidote for copper toxicity?
- A. Glucagon
- B. Aminocaproic acid
- C. Atropine
- D. Penicillamine
Correct answer: D
Rationale: Penicillamine is the specific chelating agent used for copper toxicity. It forms stable complexes with copper, which are then excreted in the urine. Glucagon is used for treating hypoglycemia, aminocaproic acid is used to treat bleeding disorders, and atropine is used as an antidote for certain types of poisoning, such as organophosphate toxicity.
2. A client is taking oral Oxycodone and Ibuprofen. The nurse should identify that an interaction between these two medications will cause which of the following findings?
- A. A decrease in serum levels of ibuprofen, possibly leading to a need for increased doses of this medication.
- B. A decrease in serum levels of oxycodone, possibly leading to a need for increased doses of this medication.
- C. An increase in the expected therapeutic effect of both medications.
- D. An increase in expected adverse effects for both medications.
Correct answer: C
Rationale: The interaction between oxycodone and ibuprofen results in an increase in the expected therapeutic effect of both medications. Oxycodone is a narcotic analgesic, while ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID). They work through different mechanisms but complement each other in pain management. When taken together, they can enhance the pain-relieving effects of each other, providing better pain relief for the client.
3. A client has a new prescription for Atenolol. Which of the following instructions should be included by the healthcare provider?
- A. Take this medication in the morning.
- B. Monitor your heart rate regularly.
- C. Avoid foods high in potassium.
- D. Increase your fluid intake.
Correct answer: B
Rationale: The correct answer is B. Atenolol is a beta-blocker that can cause bradycardia, leading to a decreased heart rate. Monitoring heart rate regularly is essential to detect any significant decreases promptly and seek medical attention. While choices A, C, and D may be relevant to the client's overall health, monitoring heart rate is the priority instruction due to the nature of Atenolol's effects. Taking the medication in the morning can be individualized based on the client's needs and preferences. Avoiding foods high in potassium and increasing fluid intake are generally beneficial but not directly related to managing the side effects of Atenolol.
4. A client has a new prescription for Atenolol. Which of the following statements should be included by the healthcare provider?
- A. Take the medication with a high-fat meal.
- B. Monitor your heart rate before taking the medication.
- C. Expect a persistent cough.
- D. Avoid foods high in fiber.
Correct answer: B
Rationale: When a client is prescribed Atenolol, a beta-blocker, they should monitor their heart rate before taking the medication. It is crucial because if the heart rate is below 60 bpm, the client needs to contact their healthcare provider for further guidance and evaluation. Choices A, C, and D are incorrect. Atenolol does not need to be taken with a high-fat meal, does not typically cause a persistent cough, and there is no need to avoid foods high in fiber when taking this medication.
5. A healthcare provider is preparing to administer Belimumab to a client with Systemic Lupus Erythematosus. Which of the following actions should the healthcare provider plan to take?
- A. Warm the medication to room temperature before administering.
- B. Administer the medication by IV bolus over 5 minutes.
- C. Dilute the medication in a 5% dextrose and water solution.
- D. Monitor the client for hypersensitivity reactions.
Correct answer: D
Rationale: Correct Answer: Monitoring the client for hypersensitivity reactions is crucial when administering Belimumab due to its known potential for severe infusion reactions and anaphylaxis. The healthcare provider should closely observe the client during the administration to promptly identify and manage any hypersensitivity reactions that may occur. Choice A is incorrect because warming Belimumab is not necessary before administration. Choice B is incorrect as Belimumab should not be administered as an IV bolus over 5 minutes; it should be given as an IV infusion over a longer duration. Choice C is incorrect as Belimumab should not be diluted in a 5% dextrose and water solution.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access